tirzepatide in the news Eli Lilly drug meets weight-loss goals obesity trial Breaking News on Tirzepatide –

Some evidence, notably from quasi-experimental bariatric surgery studies, support the concept that sustained long-term weight loss in individuals is associated with reduction of cancer incidence, particularly in women

The weight loss version of semaglutide is marketed under the brand name Wegovy

Elevated GH levels promote lipolysis and increase circulating fatty acids, effects that can contribute to insulin resistance

Tirzepatide may be appropriate for you if: Your body mass index (BMI) is 30 or higher Your BMI is 27 or higher and you have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol You have struggled to achieve or maintain meaningful weight loss through diet and exercise alone You are committed to making lifestyle changes alongside your medical weight loss program You do not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) A thorough consultation with your Wave Aesthetics provider will determine whether Tirzepatide is the right option for your specific health profile and weight loss goals